Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8430774 | 0.86 | MEN1 (0.47) | HTTLMNASMN1; SMN2FABP4KCNK3 | |
| SCHEMBL1005503 | 0.84 | HRH3 (0.47) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1006441 | 0.84 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2ALDH1A1FABP4SIGMAR1 | |
| SCHEMBL10479729 | 0.83 | LMNA (0.46) | HTTLMNASMN1; SMN2FABP4KCNK3 | |
| SCHEMBL17328065 | 0.82 | KCNH2 (0.40) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL17317506 | 0.81 | KCNH2 (0.40) | SIGMAR1 | |
| SCHEMBL9148169 | 0.79 | PTGS2 (0.45) | — | |
| SCHEMBL4218086 | 0.78 | FABP4 (0.50) | HTTLMNASMN1; SMN2ALDH1A1FABP4 | |
| SCHEMBL17317731 | 0.78 | KCNK3 (0.48) | SIGMAR1KCNK3 | |
| SCHEMBL10479643 | 0.77 | GRIA2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | claimed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | claimed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-5387693-A | Intermediates for inhibitors of cholesterol biosynthesis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-02-07 | — | — | US | disclosed |
| US-5315012-A | Prevention of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-05-24 | — | — | US | disclosed |
| US-5250561-A | Anticholesterool agents; prevention of hyperlipoproteinemia and atherosclerosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0529854-A2 | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-03-03 | — | — | EP | disclosed |
| US-5134155-A | Anticholesterol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | HTT 3487/4885LMNA 4015/4885SMN1; SMN2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.